Wieland Kiess

Kristin M. Junge

Lisa Buchenauer

Elena Elter

Katja Butter

Tibor Kohajda

Gunda Herberth

Stefan Röder

Michael Borte

Martin von Bergen

Jan C. Simon

Ulrike E. Rolle-Kampczyk

Irina Lehmann

Richard Gminski

Martin Ohlmeyer

Tobias Polte

Abstract: Background Increased use of renewable resources like sustainably produced wood in construction or for all sorts of long-lived products is considered to contribute to reducing society's carbon footprint. However, as a natural, biological material, wood and wood products emit specific volatile organic compounds (VOCs). Therefore, the evaluation of possible health effects due to wood emissions is of major interest. Objectives We investigated the effects of an exposure to multiple wood-related VOCs on asthma development. Methods A murine asthma model was used to evaluate possible allergic and inflammatory effects on the lung after short- or long-term and perinatal exposure to pinewood or oriented strand board (OSB). In addition, wood-related VOCs were measured within the German prospective mother-child cohort LINA and their joint effect on early wheezing or asthma development in children until the age of 10 was estimated by Bayesian kernel machine regression (BKMR) stratifying also for family history of atopy (FHA). Results Our experimental data show that neither pinewood nor OSB emissions even at high total VOC levels and a long-lasting exposure period induce significant inflammatory or asthma-promoting effects in sensitized or non-sensitized mice. Moreover, an exposure during the vulnerable time window around birth was also without effect. Consistently, in our mother-child cohort LINA, an exposure to multiple wood-related VOCs during pregnancy or the first year of life was not associated with early wheezing or asthma development in children independent from their FHA. Conclusion Our findings indicate that emissions from wood and wood products at levels commonly occurring in the living environment do not exert adverse effects concerning wheezing or asthma development

Wood Emissions and Asthma Development: Results from an Experimental Mouse Model and a Prospective Cohort Study

Steven D. Chernausek

Anita C. S. Hokken-Koelega

Intrauterine growth restriction in the human, the origin of many serious medical, ethical, socioeconomic and humanitarian issues, still needs in-depth studies.The current volume presents the latest research results and offers detailed discussions on clinical care. The term small for gestational age (SGA) is defined and manifestations of prenatal growth retardation and its etiology are described. Special emphasis is placed on the role of genetic defects, in particular in the IGF/GH axis. Besides, not only the immediate consequences for SGA neonates and their clinical care are examined, but also possible sequelae in childhood. A study of utmost importance considers the neurological and intellectual consequences for SGA children. It is further revealed that fetal growth restriction can adversely affect health well into adulthood, and increase the risk for type 2 diabetes. Finally, interesting insights into the causes and consequences of low birth weight in developing countries are provided.This publication is a must for pediatricians, neonatologists, obstetricians and endocrinologists, as well as anyone interested in embryology, genetics, diabetes, clinical nutrition, molecular biology and neuroendocrinology.

Causes and Consequences

Small for Gestational Age

Matthias Schwab

Johannes van den Anker

This volume provides readers with the most updated scientific information on the efficacy and safety of medicines for children and adolescents. The book enriches the understanding of pediatric pharmacotherapy for health professionals, regulatory agencies, pharmaceutical companies and learned societies. It contains important information on the pharmacodynamics and pharmacokinetics of drugs. It summarizes the latest investigations on the effects of pharmacological treatments in relation to and dependent on age, gender, fat mass and disease status. Therefore and importantly, this volume reviews the latest data on how pharmacotherapy has to be adjusted and personalized in regards to stages of development and during the pediatric lifespan from neonate through adolescence. In addition, the topic of rare diseases and special challenges for pharmacotherapy will be included and will provide readers with the necessary knowledge to handle complex diseases and treatment strategies especially in relation to pharmacotherapy of rare and orphan diseases.

Pediatric Pharmacotherapy

Francesco Chiarelli

Knut Dahl-Jørgensen

Diabetes mellitus is one of the most frequent chronic diseases affecting children and adolescents. The number of young children being diagnosed with type 1 diabetes is increasing worldwide and an epidemic of type 2 diabetes already at a young age is being

Diabetes in Childhood and Adolescence

Wieland Kiess

About

Books

Join the club